Drug Topics e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Drug Topics e-News
|
|
|
|
 |
 |
| Newest: Interprofessional communication |
| For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here |
|
|
|
Survey
This month we would like to know...
AMA is seeking repeal of the PPACA reimbursement rule that requires prescriptions for OTCs. Do you agree with AMA?
|
|
|
Antibacterial drug use in children is associated with a dose-dependant increased risk of acquiring community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), according to the results of a population-based, case-control study reported online August 1 in the Archives of Pediatrics & Adolescent Medicine.
Read full article. |
 |
|
|
To confirm your e-newsletter subscription, click here.
To ensure future delivery of email newsletters from
Drug Topics, please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff
|
 |
A discussion generated by
Drug Topics’ readers, editorial staff, and advisory board
Brandon Eldridge is a practicing community pharmacist in Missouri and Illinois. |
Pharmacists have reached into their pockets to assist needy patients on many occasions. But when the patient makes no effort to take responsibility and the cost to the pharmacist becomes painful, where should the line be drawn? Read full article.
|
Medicare Part D beneficiaries who are responsible for 100% of previously subsidized prescription costs are twice as likely to discontinue their medications, according to a new study published in PLoS Medicine.
Read full article. |
|
FDA has approved 2 new strengths (11.25 mg and 30 mg) for 3-month administration of leuprolide acetate for depot suspension (Lupron Depot-PED, Abbott) for the treatment of children with central precocious puberty.
Read full article. |
|
|
FDA has approved vemurafenib (Zelboraf, Daiichi Sankyo and Genentech), the second melanoma drug this year to improve overall survival. Vemurafenib is indicated for the treatment of patients with late-stage (metastatic) or unresectable melanoma, the most dangerous type of skin cancer. Read full article.
|
|
Apricus Biosciences and its wholly owned subsidiary, NexMed USA, have received FDA approval for over-the-counter sales of antifungal drug Tolnaftate-D, containing the company's NexACT technology, which transiently loosens the tight junction between the cells of the sealed skin to allow more permeation. Read full article.
|
|
Once-daily oral rivaroxaban (Xarelto, Bayer), a direct factor Xa inhibitor, appears to be as effective as dose-adjusted warfarin in preventing stroke or major embolism in patients with nonvalvular atrial fibrillation, according to a study published online August 10 in the New England Journal of Medicine. Read full article.
|
|
As the influenza season approaches, Raleigh, N.C.-based Kerr Drug is stepping up its vaccination program. The retail chain is providing vaccinations during operating hours at most of its stores throughout North Carolina, with no appointment necessary. Kerr Drug pharmacists also will provide flu vaccines at its booth during the 2011 North Carolina State Fair in Raleigh, October 13 through October 23. Read full article.
|
|
Pharmacy and dental organizations are uniting to promote oral health and raise public awareness of dry mouth, a side effect commonly caused by taking prescription and over-the-counter medications. Read full article.
|
|
In this section we showcase products and product news that ran up against space limitations or fell outside the parameters of recently featured categories in the print edition. Look for more OTC Product News in upcoming issues of the Community Pharmacists' Report. Read full article.
|
Career Opportunities
|
Meetings and Events
August 27-30, 2011 NACDS Pharmacy & Technology Conference
Boston
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
703-683-5678
September 26-27, 2011 2nd Annual Pharmaceutical Labeling Summit
Washington, D.C.
Contact:
Jeff Grizzel, Conference Director
FDA News
300 N. Washington St., #200
Falls Church, VA 22046-3431
703-538-7668
jgrizzel@fdanews.com
www.fdanews.com/PharmaLabeling
October 6-7, 2011 NCPA Diabetes Accreditation
Standards-Practical Applications (DASPA)
Nashville, TN
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
October 8-12 2011 NCPA Annual Convention
Nashville, TN
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
November 29, 2011 NACDS Foundation 13th Annual Dinner
New York, NY
Contact:
Jennifer Sargeant, Manager, Foundation Programs and Education, NACDS
703-837-4224
|
|
|
|
| Contact Us |
Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
